Jeffrey M. Leiden

2015 - Vertex Pharmaceuticals

In 2015, Jeffrey M. Leiden earned a total compensation of $28.1M as Chairman, President & CEO at Vertex Pharmaceuticals, a 23% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$3,463,200
Option Awards$16,286,939
Salary$1,297,692
Stock Awards$7,038,885
Other$13,110
Total$28,099,826

Leiden received $16.3M in option awards, accounting for 57.96% of the total pay in 2015.

Leiden also received $3.5M in non-equity incentive plan, $1.3M in salary, $7M in stock awards and $13.1K in other compensation.

Rankings

In 2015, Jeffrey M. Leiden's compensation ranked 43rd out of 13,622 executives tracked by ExecPay. In other words, Leiden earned more than 99.7% of executives.

ClassificationRankingPercentile
All
43
out of 13,622
100th
Division
Manufacturing
13
out of 5,195
100th
Major group
Chemicals And Allied Products
8
out of 1,824
100th
Industry group
Drugs
7
out of 1,493
100th
Industry
Pharmaceutical Preparations
6
out of 1,153
100th
Source: SEC filing on April 28, 2017.

Leiden's colleagues

We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2015.

2015

David Altshuler

Vertex Pharmaceuticals

Chief Scientific Officer

2015

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2015

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2015

Jeffrey Chodakewitz

Vertex Pharmaceuticals

Chief Medical Officer

News

In-depth

You may also like